Clinical Trial: High-dose Antioxidants for Central Serous Chorioretinopathy

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: High-dose Antioxidants for Central Serous Chorioretinopathy

Brief Summary: Central serous chorioretinopathy (CSC) is the serous neurosensory detachment that usually involves the macular area. It is common in patients between 30-50 years old and effects male more often than female with the ratio of 5-10. The common risk factors are psychologic stress, type A personality, systemic steroid use, hypertension and pregnancy. The treatment is usually observation especially in the first three-months. The laser or photodynamic therapy should be considered when the condition does not improve after that time. Nevertheless, the pathogenesis of CSC is still not well understood but the study from indocyanine green angiography showed the choroidal vascular hyperpermeability and abnormal leakage. The causes of this abnormality are supposed to be from nitric oxide, prostaglandins or even free oxidative radicals. From this hypothesis, the oxidative process might be involved in the pathogenesis of the disease especially in the early stage. This study is to determine the effect of antioxidants drugs in the acute stage of CSC and to determine whether they can improve the outcomes of the disease.

Detailed Summary:
Sponsor: Prince of Songkla University

Current Primary Outcome: visual acuity and central macular thickness [ Time Frame: 6 months ]

Original Primary Outcome: Same as current

Current Secondary Outcome: fluorescein leakage at the third month [ Time Frame: 6 months ]

Original Secondary Outcome: Same as current

Information By: Prince of Songkla University

Dates:
Date Received: August 20, 2009
Date Started: December 2004
Date Completion:
Last Updated: December 29, 2009
Last Verified: December 2009